Physician profile
Elie Saade
NPI 1164654455
$32,249.94
in general payments reported to CMS, 2019-2025
19 companies · $7,352 in 2025
The $7,352 reported for 2025 was more than what 91% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,874 · 2020: $5,213 · 2022: $191 · 2023: $12K · 2024: $1,335 · 2025: $7,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Food and Beverage: $930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,042.50 |
| Food and Beverage | $930.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Research & Development, LLC | $9,579.64 | 2023-2025 | |
| Pfizer INC. | $8,153.87 | 2019-2025 | |
| Janssen Global Services, LLC | $7,495.00 | 2023-2024 | |
| Sanofi Pasteur INC. | $5,026.18 | 2020 | |
| Merck Sharp & Dohme LLC | $346.47 | 2019-2025 | Dificid, Zerbaxa, Recarbrio |
| Gilead Sciences, INC. | $330.67 | 2019-2025 | |
| Melinta Therapeutics, LLC | $267.30 | 2019-2024 | Orbactiv, Kimyrsa, Vabomere |
| Insmed, INC. | $210.56 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $169.32 | 2025 | Zevtera |
| Janssen Biotech, INC. | $157.79 | 2019-2023 | Symtuza |
| Shionogi INC | $116.47 | 2023-2024 | Fetroja |
| Tetraphase Pharmaceuticals, INC. | $103.83 | 2019-2020 | |
| Janssen Products, Lp | $84.99 | 2022 | |
| Abbvie INC. | $65.60 | 2024-2025 | |
| Allergan, INC. | $56.46 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $42.99 | 2022-2025 | Cresemba |
| Nabriva Therapeutics, Plc | $17.41 | 2020 | |
| Napo Pharmaceuticals INC | $13.40 | 2019 | |
| Theratechnologies INC. | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elie Saade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.